ClinicalTrials.gg

Program

KAT6/KAT7 Inhibitor PF-08032562

Its studies are mostly in Triple Negative Breast Neoplasms, led by Pfizer.

Furthest: phase 1, since Dec 4, 20251 company-led study, 1 open or runningNext primary completion: Apr 14, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Dec 4, 2025Dec 4, 2025Apr 14, 2029phase 1 · NCT07318805

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07318805 · 260 planned · United States, France, Spain

Ahead

  1. Apr 14, 2029Primary completion: phase 1 study in Breast NeoplasmsNCT07318805

TargetBeta

“An orally bioavailable small molecule inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3), KAT6B (MORF; MOZ2; MYST4) and KAT7 (HBO1; MYST2), ”NCIt, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07318805Breast Neoplasms · United States, France, Spain1RecruitingApr 14, 2029260

How it is read

Names in the registry

  • “PF-08032562”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.